CVS Health Reaches $440 Million Settlement with DOJ Over Omnicare Fraud Case
CVS Health, a prominent player in the healthcare industry, and its subsidiary Omnicare, have reached a crucial settlement agreement with the U.S. Department of Justice (DOJ). The agreement requires CVS Health to pay $440 million, resolving a substantial judgment of nearly $950 million levied against Omnicare amidst an ongoing fraud case.
Background of the Case
In April 2025, a federal jury concluded that Omnicare had illegally submitted over 3.3 million prescription claims from 2010 to 2018, leading to $135.6 million in overpayments. Subsequently, in July 2025, a judge mandated Omnicare to pay $948.8 million in fees and damages, exacerbating the financial pressure on the company.
Settlement Details and Payment Timeline
Under the terms of the new agreement, CVS Health committed to an initial payment of $130 million within 14 days of the settlement’s activation. The remaining $310 million is scheduled to be paid by March 15, 2028.
Importantly, the settlement with the DOJ hinges on the successful sale of Omnicare to GenieRx Holdings. Omnicare declared bankruptcy in September 2025 while grappling with the repercussions of the False Claims Act case, prompting CVS to announce its sale to GenieRx earlier this year.
Implications of the Agreement
The court filing elaborates that the agreement facilitates the confirmation of consensual Chapter 11 plans for debtors, averting prolonged and costly litigation. It also outlines provisions for addressing DOJ and CVS claims, enhancing the likelihood of fully compensating all general unsecured claims.
A CVS Health spokesperson emphasized that the settlement does not imply admission of liability or wrongdoing, but rather aims to circumvent the protracted and expensive nature of further legal proceedings. “We are pleased to put this matter behind us as part of a successful conclusion to the Omnicare Chapter 11 case,” the spokesperson stated to Fierce Healthcare.
Future Prospects for Omnicare
During its bankruptcy proceedings, Omnicare sought $110 million in debtor-in-possession financing to sustain operations, using this period to explore potential restructuring or sale options. The anticipated sale to GenieRx, a collaboration between Milrose Capital and Integro Asset Management, is expected to conclude by the year’s end. GenieRx specializes in virtual healthcare and medication services, promising a new direction for Omnicare.
CVS Health’s acquisition of Omnicare in 2015 initially aimed to bolster its service capabilities. However, the fraud case involving a whistleblower lawsuit filed in 2015 by a former Omnicare pharmacist, which the DOJ joined in 2019, exposed significant operational challenges.
The jury determined that while Omnicare filed numerous fraudulent claims, none resulted in harm to the federal government. This legal resolution marks a pivotal moment for CVS Health and Omnicare, offering a path forward amidst complex legal and financial challenges.
For more detailed information, you can read the full article Here.
“`
